| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Arbutus Biopharma Corporation$4.58
+0.17 (+3.85%)
D 35Pipeline Score Overvalued Pharma · Commercial
Market Cap
841.51 M
EPS
0.83
P/E Ratio
5.18 $
Value Trade
7.43 M
SEC Financials
Q1 2026Dilution Risk
Revenue
179.13 M
R&D Expenses
4.12 M
Operating CF
-8.11 M
Total Assets
277.16 M
Total Liabilities
16.99 M
Equity
260.18 M
D/E Ratio
12,345
1.16 %
Week
-2.47 %
1 Month
3.57 %
3 Month
4.57 %
6 Month
55.36 %
5 Year
-39.73 %
All Time
Cash Data
Cash Position
95.23 M
Monthly Burn
2.70 M
Runway
33.8 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
6.80 M
52 Week Range
3.04 - 5.10
% held by Insiders
20.46 %
% held by Institutions
66.66 %
Enterprise Value
750.19 M
Total Shares
196.82 M
Short %
11.2 %
Float Shares
156.47 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D35
Pipeline Score $273M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.3x
rNPV / MCap Top 49%
Micro Cap (rank 463 of 905)
Percentile RankArbutus Biopharma Corporation faces pipeline headwinds (35/100), with $683M risk-adjusted pipeline value, led by AB-729 in Chronic Hepatitis b (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AB-729 Small molecule | Chronic Hepatitis b | Phase 2 | NCT04980482 | 21% | $193M | COMPLETED | 43 | - | - | May 21, 2025 | - | MEDIUM May 30, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Imdusiran | Chronic Hepatitis B Virus (cHBV) | Phase 2a | 2025-06-25 | |||
Imdusiran | Chronic Hepatitis B Virus (cHBV) | Phase 2a | 2025-06-25 | |||
Imdusiran | Chronic Hepatitis B Virus (cHBV) | Phase 2a | 2025-06-25 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ABUS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ABUS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ABUS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ABUS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ABUS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ABUS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ABUSArbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported strong financial results for Q1 2026, with total revenue reaching $179.1 million, largely due to a settlement with Moderna. The FDA granted Fast Track designation for imdusiran, aimed at treating chronic hepatitis B, enhancing its development prospects. The company maintains a robust cash position of $95.2 million.
Read more →ABUSArbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Arbutus Biopharma has received Fast Track designation from the FDA for its therapeutic imdusiran, aimed at treating chronic hepatitis B. This designation helps streamline the drug's development and review process, potentially leading to quicker access for patients. Imdusiran has previously demonstrated effective results, achieving functional cures in several patients during clinical trials. The company is optimistic about the continued collaboration with the FDA to facilitate the drug's progress through regulatory hurdles.
Read more →ABUSArbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported solid fourth quarter and year-end financial results for 2025, highlighting a cash position of $91.5 million. The company achieved a significant $2.25 billion settlement with Moderna over patent infringement related to lipid nanoparticle delivery technology. Additionally, two more patients from its imdusiran clinical trials reached functional cure status, reflecting progress in its hepatitis B program. However, the company reported a net loss of $33.5 million for the year, though this marks an improvement from the previous year's losses.
Read more →ABUSCase No.
The article discusses the ongoing patent litigation between Arbutus Biopharma and Moderna. Arbutus asserts patent infringement claims against Moderna related to lipid nanoparticles used in its COVID-19 vaccine. Moderna has presented defenses, including expert opinions, but faces challenges due to previous inter partes review (IPR) decisions. The legal proceedings may have significant implications for both companies, particularly regarding their respective patent rights in the biotechnology field.
Read more →ABUSGenevant & Arbutus LNP Litigation Lindsay Androski Special Counsel, Genevant CEO, Arbutus Matt Gline CEO, Roivant
Genevant and Arbutus are actively involved in litigation against Moderna and Pfizer/BioNTech, alleging patent infringement regarding their lipid nanoparticle (LNP) technology used in COVID-19 vaccines. Initial court rulings have been favorable for Genevant, with significant revenue generated from the vaccines under dispute. However, the litigation process is expected to continue for several years, with key trials scheduled for 2026. The companies aim to secure restitution for the unauthorized use of their patents.
Read more →ABUSArbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma reported its third quarter 2025 financial results, highlighting a strategic focus on its imdusiran program for chronic hepatitis B. The company noted that 46% of patients in Phase 2a trials were able to discontinue nucleos(t)ide analogue therapy. Despite a decrease in revenue and ongoing restructuring, the long-term efficacy of imdusiran remains promising.
Read more →ABUSArbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Arbutus Biopharma Corporation announced that four abstracts, including clinical data on imdusiran and AB-101, have been accepted for presentation at AASLD – The Liver Meeting 2025. The AB-101 abstract has been designated as a Poster of Distinction. The findings highlight the safety and potential efficacy of imdusiran in chronic hepatitis B patients.
Read more →ABUSArbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma reported its financial results for Q2 2025, showcasing a total revenue of $10.7 million, driven by the conclusion of its partnership with Qilu in Greater China. The company now holds global rights for its lead compound, imdusiran. Key personnel changes include the addition of Dr. Roger Sawhney to the Board and Dr. Harry Janssen to the Scientific Advisory Board. Despite the strong revenue figures, the company continues to navigate ongoing legal challenges regarding its intellectual property, particularly against Moderna and Pfizer/BioNTech.
Read more →ABUSArbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Arbutus Biopharma has reacquired the rights to imdusiran from Qilu Pharmaceutical, concluding their strategic partnership. The company is focusing on advancing its pipeline efficiently, with imdusiran having shown promising results in achieving functional cures in patients. Additionally, Arbutus has established a new Scientific Advisory Board to guide its chronic hepatitis B virus treatment strategies.
Read more →ABUSArbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported its first quarter 2025 financial results, highlighting the success of their imdusiran therapy, which has functionally cured eight patients with chronic hepatitis B. Their oral PD-L1 inhibitor, AB-101, has demonstrated a strong safety profile and high receptor occupancy in early trials. The company also introduced Andrew J. Sung as General Counsel, enhancing their legal expertise. With a solid financial base of $113 million, Arbutus continues to focus on its clinical development efforts.
Read more →ABUSArbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
Arbutus Biopharma presented promising clinical trial data for its HBV treatments, imdusiran and AB-101, at the EASL Congress 2025. Imdusiran achieved functional cure rates in chronic hepatitis B patients when combined with VTP-300 and low-dose nivolumab. AB-101 was shown to be safe and well-tolerated in a Phase 1a/1b trial, indicating high receptor occupancy without liver dysfunction.
Read more →ABUSArbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
Arbutus Biopharma announced that five abstracts, including a late-breaker, will be presented at the EASL Congress 2025. The abstracts cover data on imdusiran and AB-101, showcasing promising results in treating chronic hepatitis B. Notably, imdusiran has shown potential for achieving functional cure rates when combined with other therapies. The presentations are scheduled for May 8, 2025, in Amsterdam.
Read more →ABUSArbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported its fourth quarter and year-end 2024 financial results, emphasizing a focus on clinical development and operational efficiency. The company appointed Tuan Nguyen as Chief Financial Officer amid a significant workforce reduction of 57%. Despite a strong cash position of $123 million, total revenue saw a decline from the previous year, primarily due to changes in partnership dynamics and license royalties. The company is moving forward with plans for its imdusiran pipeline, aiming for a Phase 2b clinical trial and expects 2025 to bring transformative changes.
Read more →ABUSGenevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Genevant Sciences and Arbutus Biopharma have initiated five international lawsuits against Moderna for alleged patent infringements related to their lipid nanoparticle (LNP) technology. The enforcement actions target activities in 30 countries and seek monetary relief and injunctions against Moderna's Spikevax and other products. This legal action expands on an ongoing case in the U.S. District Court scheduled for trial in September 2025.
Read more →ABUSArbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
Arbutus Biopharma Corporation has appointed Lindsay Androski as its new CEO, replacing Michael J. McElhaugh. Alongside her appointment, four new directors have joined the board, with all previous members stepping down. The company plans to pause investor meetings while the new leadership reviews its strategic options, particularly for its hepatitis B programs.
Read more →ABUSArbutus Provides 2025 Corporate and Financial Update
Arbutus Biopharma Corporation has announced its corporate objectives and financial updates for 2025, highlighting positive results from its Phase 2a clinical trials of imdusiran and interferon for treating chronic hepatitis B virus (cHBV) infection. The company plans to initiate a Phase 2b clinical trial in the first half of 2025, supported by solid financial resources and reduced net cash burn compared to 2024. With an existing cash balance and strategic partnerships, Arbutus aims to fund its operations through early 2028. Furthermore, the company is involved in ongoing legal matters regarding its patented LNP technology used by major pharmaceutical firms.
Read more →ABUSArbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Arbutus Biopharma Corporation will participate in the H.C Wainwright @ Home virtual fireside chat on December 3, 2024. The company focuses on developing a functional cure for chronic hepatitis B virus (cHBV), leveraging its expertise in virology. Arbutus has a promising pipeline, including the RNAi therapeutic imdusiran, which has demonstrated meaningful success in patients, and the PD-L1 inhibitor AB-101 currently in trial. Interested parties can access the webcast on the company’s investor relations page.
Read more →ABUSArbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Arbutus Biopharma announced promising results from its IM-PROVE I Phase 2a clinical trial, demonstrating that its RNAi therapeutic imdusiran combined with a short course of pegylated interferon achieved a 50% functional cure rate in certain patients with chronic hepatitis B virus (cHBV). The overall functional cure rate observed was 25%. The results, which will be shared at AASLD's upcoming conference, indicate that this combination therapy holds significant potential for patients struggling with cHBV. The treatment's safety profile was noted as generally favorable, with no serious adverse events related to the therapies reported.
Read more →ABUSArbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Arbutus Biopharma announced promising results from its IM-PROVE I Phase 2a clinical trial for its RNAi therapeutic imdusiran, showing a functional cure rate of 50% among HBeAg-negative patients with low baseline HBsAg levels. The overall functional cure rate reached 25%. These findings highlight the potential effectiveness of combining imdusiran with pegylated interferon alfa-2a treatment. Such results, to be presented at the upcoming AASLD conference, are expected to generate interest in addressing the significant unmet medical need for chronic hepatitis B virus infection.
Read more →ABUSArbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Arbutus Biopharma and Barinthus Biotherapeutics announced new data from the Phase 2a IM-PROVE II trial highlighting the effectiveness of combining imdusiran, VTP-300, and low-dose nivolumab in achieving HBsAg loss in chronic hepatitis B patients. The trial showed that 23% of participants reached HBsAg loss by Week 48, with significantly reduced HBsAg levels compared to other groups. The treatment was well tolerated, without immune-related adverse events, supporting further exploration of this regimen in treating chronic hepatitis B.
Read more →ABUSArbutus to Present at Jefferies London Healthcare Conference
Arbutus Biopharma Corporation will present at the Jefferies London Healthcare Conference on November 21, 2024. The company aims to provide insights into its development of a functional cure for chronic hepatitis B virus infection. Their innovative pipeline includes RNAi therapeutic imdusiran and an oral PD-L1 inhibitor AB-101, both showing progress in clinical trials. Investors will have opportunities for one-on-one meetings during the event.
Read more →ABUSArbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Arbutus Biopharma reports its financial results for Q3 2024, revealing a focus on progressing its clinical trials for cHBV treatments imdusiran and AB-101. The company reports promising tolerability and safety results in its drug trials, with a notable cash runway extending into late 2026. However, it also faces challenges, including decreased revenues and ongoing litigation regarding its intellectual property. Critical upcoming presentations at the AASLD - The Liver Meeting 2024 may provide further data on its treatment programs.
Read more →ABUSArbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation has announced that it will report its third quarter 2024 financial results on November 6, 2024. This will include a press release at 7:30 a.m. ET followed by a conference call/webcast at 8:45 a.m. ET. The company's pipeline features notable candidates such as imdusiran and AB-101 for the treatment of chronic hepatitis B virus infection, with imdusiran currently in two Phase 2a trials.
Read more →ABUSArbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting 2024
Arbutus Biopharma has announced that data on their RNAi therapeutic, imdusiran, has been accepted for presentation at the AASLD - The Liver Meeting 2024. Four poster presentations will showcase important findings from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials. Key results include insights into immune biomarker responses during treatment and confirmation of the target site's conservation in chronic hepatitis B patients. This highlights imdusiran's potential effectiveness against various HBV genotypes and may signify a step towards a functional cure for chronic HBV infection.
Read more →ABUSArbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Arbutus Biopharma Corporation (Nasdaq: ABUS) will present at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on October 8, 2024, and will host one-on-one meetings. The company focuses on developing a functional cure for chronic hepatitis B virus (cHBV) infection, with promising candidates like imdusiran and AB-101 undergoing clinical trials. Data from these trials suggest potential efficacy in reducing surface antigens and boosting immune responses, making Arbutus a notable player in the hepatitis B therapeutic landscape.
Read more →ABUSArbutus to Participate in Two Upcoming Investor Conferences
Arbutus Biopharma Corporation (Nasdaq: ABUS) will participate in two upcoming investor conferences in New York, scheduled for September 9 and 10, 2024. The events include a formal presentation at the H.C. Wainwright Global Investment Conference and a fireside chat at the Baird Global Healthcare Conference. The management team will also host one-on-one meetings, providing opportunities for direct engagement with investors. Arbutus is focused on developing a functional cure for chronic hepatitis B, with ongoing clinical trials for its therapies.
Read more →ABUSArbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Arbutus Biopharma has reported its second-quarter financial results for 2024, highlighting promising data from the IM-PROVE I clinical trial of imdusiran, where 67% of patients achieved undetectable HBsAg levels. The company is pivoting its strategy, focusing resources on a Phase 2b trial for imdusiran by discontinuing certain HBV research efforts and reducing its workforce by 40%. Despite a reported decline in revenue, Arbutus anticipates its financial position will support operations through the fourth quarter of 2026, following strategic organizational changes.
Read more →ABUSArbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced the schedule for its second quarter 2024 financial results and corporate update, set for August 1, 2024. The company is focused on developing treatments for chronic hepatitis B virus (cHBV) infection and is currently running clinical trials for its candidates, including imdusiran and AB-101. Investors can expect comprehensive insights into the company's progress and financial health during the upcoming conference call and webcast.
Read more →ABUSTreatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Arbutus Biopharma announced promising preliminary data from its Phase 2a trial of imdusiran and VTP-300, presented at the EASL Congress. The treatment showed statistical significance in reducing HBsAg levels in patients on standard nucleos(t)ide analogue therapy. Notably, 94% of patients in the treatment group achieved HBsAg levels below 100 IU/mL by the end of treatment, and 84% qualified to stop NA therapy. The findings support the potential of this combination therapy as a functional cure for chronic hepatitis B virus infection.
Read more →ABUSArbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
Arbutus Biopharma Corporation announced promising results from its Phase 2a clinical trial, IM-PROVE I, demonstrating that imdusiran combined with pegylated interferon (IFN) can lead to sustained undetectable levels of HBsAg in patients with chronic hepatitis B virus (cHBV) infection. Notably, 33.3% of patients achieved this outcome at the end of treatment, which was maintained for 24 weeks post-treatment. Importantly, the combination therapy showed a favorable safety profile with no serious adverse events reported. These results are anticipated to provide significant advancements in the search for a functional cure for HBV.
Read more →ABUSArbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
Arbutus Biopharma announced promising results from its Phase 2a clinical trial IM-PROVE I, where the combination of imdusiran and pegylated interferon resulted in 33.3% of patients achieving sustained undetectable levels of HBsAg. This benefit was maintained for at least 24 weeks post-treatment. Six patients who discontinued all therapies also retained undetectable HBV DNA levels. The results were shared at the EASL Congress 2024, highlighting the potential of this treatment regimen for patients with chronic Hepatitis B virus infection.
Read more →ABUSArbutus to Participate in Jefferies Global Healthcare Conference
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the Jefferies Global Healthcare Conference taking place on June 5, 2024, where the management will present and host one-on-one meetings. The company focuses on developing therapeutics for chronic hepatitis B virus (cHBV) and is advancing its pipeline, which includes compounds like imdusiran and AB-101. Notably, imdusiran is currently involved in multiple Phase 2a trials, demonstrating its potential in managing cHBV infections.
Read more →ABUSArbutus to Present Imdusiran Data at EASL Congress 2024
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced that two abstracts related to their therapeutic candidate imdusiran will be presented at the EASL Congress 2024 in Milan, Italy. The studies highlight the efficacy of imdusiran in achieving HBsAg loss in chronic hepatitis B patients and maintaining lower HBV surface antigen levels. These findings indicate that imdusiran, in addition to its previously demonstrated safety, may offer a significant therapeutic advantage in the treatment of chronic hepatitis B virus infections. The presentations are scheduled for June 5 and 6, 2024.
Read more →ABUSArbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation has reported its first quarter 2024 financial results and provided a corporate update, highlighting progress in its hepatitis B virus (HBV) treatment pipeline. The company plans to present end-of-treatment data from several clinical trials at the EASL Congress in June 2024. Arbutus maintains a strong cash position expected to last into the second quarter of 2026, even amid a significant reduction in revenue year-over-year. Ongoing litigation against Moderna and Pfizer/BioNTech regarding its intellectual property could present ongoing risks for the company.
Read more →ABUSArbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
Arbutus Biopharma Corporation has announced the retirement of its co-founder and Chief Scientific Officer, Dr. Michael Sofia, effective December 31, 2024. Dr. Sofia is recognized for his significant contributions to antiviral drug development and has played a key role in advancing Arbutus' mission to find a functional cure for chronic hepatitis B virus (cHBV). The company’s interim president has expressed gratitude for Dr. Sofia's leadership and accomplishments, indicating a positive outlook for future clinical developments.
Read more →ABUSArbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation (Nasdaq: ABUS) has scheduled the release of its first quarter 2024 financial results and corporate update for May 2, 2024. A press release will be issued at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. The company is focusing on developing therapeutics for chronic hepatitis B virus, with ongoing Phase 2a and Phase 1 trials for its compounds imdusiran and AB-101, respectively. A live webcast of the conference call will be available on Arbutus' website, along with an archived version post-event.
Read more →ABUSArbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
Arbutus Biopharma has received a favorable claim construction ruling from the U.S. District Court in Delaware regarding its patent infringement lawsuit against Moderna. The court agreed with Arbutus's interpretations of several patent claim terms related to lipid nanoparticles used in Moderna's COVID-19 vaccine. This decision is expected to bolster Arbutus's case as it seeks damages for the alleged infringement of its patented technology. Arbutus aims to protect its intellectual property while pursuing fair compensation for the use of its innovations.
Read more →ABUSArbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation has reported its financial results for the fourth quarter and year-end 2023, highlighting a solid financial position with $132 million in cash. The company anticipates significant clinical milestones in 2024, including multiple data readouts from ongoing trials with its key assets, imdusiran and AB-101. Despite these advancements, revenue decreased significantly compared to the previous year, which raised concerns regarding the company's financial performance. The company is actively defending its intellectual property in ongoing litigation concerning its LNP technology, with a trial date set for April 2025.
Read more →ABUSArbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation has scheduled the release of its fourth quarter and year-end 2023 financial results for February 29, 2024. The event will include a press release followed by a conference call and webcast. The company is focused on developing a functional cure for chronic hepatitis B virus infection, leveraging its innovative pipeline including imdusiran and AB-101. The upcoming updates will provide insights into their financial performance and corporate strategies.
Read more →ABUSArbutus Announces 2024 Corporate Objectives and Provides Financial Update
Arbutus Biopharma Corporation has outlined its corporate objectives for 2024, including multiple clinical trials for its pipeline therapies, imdusiran and AB-101. The company anticipates announcing critical data from these trials in the coming year, with a strong financial position indicated by a cash runway extending to Q1 2026. Additionally, the firm continues its litigation against Moderna and Pfizer/BioNTech regarding its patented LNP technology, with legal proceedings expected to last into 2025. Overall, Arbutus remains focused on developing treatments for chronic hepatitis B virus infections.
Read more →ABUSArbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting
Arbutus Biopharma and Barinthus Bio presented preliminary data from their Phase 2a clinical trial combining imdusiran and VTP-300, showing encouraging results at AASLD 2023. The trial demonstrated a meaningful reduction in HBsAg levels and signs of immune activation in patients. Notably, all patients treated with the combination maintained low HBsAg levels, allowing them to discontinue nucleos(t)ide analogue therapy. Safety data indicated that both treatments were well-tolerated with no serious adverse events reported.
Read more →ABUSArbutus Announces CEO, William Collier, to Retire December 31, 2023
Arbutus Biopharma Corporation announced that CEO William Collier will retire at the end of 2023, with COO Michael J. McElhaugh stepping in as interim CEO from January 1, 2024. Collier expressed gratitude for his leadership role and the achievements made during his tenure, particularly the advancement of the HBV asset, imdusiran. The transition aims to maintain stability as the company continues its efforts to develop therapeutics for chronic hepatitis B virus. The company’s outlook remains to leverage its virology expertise while navigating potential uncertainties during this transitional period.
Read more →ABUSArbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation has reported its financial results for Q3 2023, indicating a net loss of $20.1 million. The company is set to present preliminary data at the AASLD 2023 event, focusing on its RNAi therapeutic imdusiran combined with VTP-300. Despite workforce reductions and declining revenue, Arbutus has extended its cash runway to the first quarter of 2026. Furthermore, organizational changes will include the retirement of CEO William Collier, with COO Michael J. McElhaugh stepping in as interim CEO.
Read more →ABUSArbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation (Nasdaq: ABUS) is set to release its third quarter 2023 financial results on November 7, 2023, at 7:30 a.m. ET. The company will also host a conference call/webcast to discuss these results later that day at 8:45 a.m. ET. Arbutus continues to develop its therapeutic candidates, such as imdusiran for chronic hepatitis B, and is also exploring applications in oncology. The company emphasizes its expertise in virology and aims to provide innovative treatment solutions.
Read more →ABUSArbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
Arbutus Biopharma Corporation will participate in the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference on October 25, 2023. The management team will also host one-on-one meetings for investors. The company is focused on developing novel therapeutics for chronic hepatitis B, including imdusiran and AB-101, with promising clinical data supporting their efficacy. Archived access to the presentation will be available after the event.
Read more →ABUSArbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2023
Arbutus Biopharma Corporation has announced that clinical data related to its leading HBV therapeutic, imdusiran (AB-729), and preclinical data on its PD-L1 inhibitor will be presented at the upcoming AASLD - The Liver Meeting 2023. The presentations include a late-breaking poster about imdusiran's pharmacodynamics and safety in patients with chronic hepatitis B. The company aims to spotlight its innovative therapeutic strategies during this prestigious event in Boston from November 10-14, 2023.
Read more →ABUSArbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
Arbutus Biopharma Corporation has announced notable updates in their pipeline, including the dosing of the first subject in a Phase 1a/1b clinical trial for its oral PD-L1 inhibitor, AB-101. The company is focusing its resources on hepatitis B virus (HBV) treatments while discontinuing programs related to coronavirus and other compounds due to safety concerns. Financially, Arbutus has extended its cash runway through Q3 2025, indicating a positive outlook for ongoing clinical developments. Preliminary results from ongoing trials are expected by early 2024.
Read more →ABUSArbutus Reports Second Quarter 2023 Financial Results and Corporate Update
Arbutus Biopharma Corporation reported its financial results for the second quarter of 2023, highlighting significant milestones in its clinical trials. The company received regulatory approval to advance AB-101 into a Phase 1 trial and reported favorable results for AB-729 showing continued HBsAg declines. However, the company experienced a notable decrease in revenue, falling to $4.7 million from $14.2 million in the previous year. Arbutus also reported substantial cash expenditures, with a projected runway into the first quarter of 2025.
Read more →ABUSArbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation has announced the schedule for its second quarter 2023 financial results and corporate update, set for August 3, 2023. The company specializes in developing therapeutics targeting viral diseases, including Hepatitis B and coronaviruses. Their lead compound, AB-729, is being evaluated for its potential in HBV treatment. The press release will be made available on the company's website along with a live webcast of the conference call.
Read more →ABUSArbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
Arbutus Biopharma Corporation announced the appointment of Dr. Melissa V. Rewolinski to its Board of Directors, effective July 12, 2023. Dr. Rewolinski has over 20 years of experience in strategic, operational, and drug development roles within the pharmaceutical industry. Her expertise is expected to support Arbutus in advancing its pipeline, particularly for treatments targeting Hepatitis B virus (HBV) and coronaviruses. The company is focusing on innovative therapies, including an RNAi therapeutic designed to potentially provide a functional cure for chronic HBV.
Read more →ABUSArbutus Appoints Two New Executives
Arbutus Biopharma Corporation has announced the appointment of Dr. Karen Sims as Chief Medical Officer and Christopher Naftzger as General Counsel and Chief Compliance Officer. Dr. Sims, an experienced clinical development executive, has been with Arbutus since 2017 and has been integral to the development of its lead RNAi therapeutic, AB-729. Mr. Naftzger brings over 25 years of legal experience, succeeding Liz Howard, who will continue to support the company in an advisory capacity. These appointments aim to bolster the executive team as Arbutus advances its pipeline of therapeutics targeting chronic HBV and other viral diseases.
Read more →ABUSArbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
Arbutus Biopharma Corporation has initiated dosing of the first patient in an additional treatment arm of its Phase 2a triple combination clinical trial. This trial expands on the use of AB-729 and VTP-300 by incorporating the PD-1 monoclonal antibody nivolumab. The study aims to investigate the potential for enhanced immune responses and reduction of HBsAg in patients with chronic hepatitis B. Preliminary data from this expanded treatment arm is anticipated in 2024, building on data expected from the original trial by late 2023.
Read more →ABUSArbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
Arbutus Biopharma presented preliminary data on its Phase 2a clinical trial that evaluates the combination of AB-729 and pegylated interferon alfa-2a for chronic hepatitis B virus (cHBV) patients at the EASL Congress 2023. The treatment was well tolerated, with many patients experiencing declining HBsAg levels, suggesting potential effectiveness. However, the results come from a small patient sample and further follow-up is needed, as no sustained seroclearance has been achieved so far.
Read more →ABUSArbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
Arbutus Biopharma Corporation announced that two abstracts related to its therapies, AB-729 and AB-836, have been accepted for poster presentations at the upcoming EASL Congress 2023. The first abstract highlights promising safety and efficacy results for AB-729 in treating chronic HBV infection. The second abstract discusses the research findings on HBV core protein variants in patients treated with AB-836. Both presentations will take place from June 21 to 24, 2023, in Vienna, Austria.
Read more →ABUSArbutus to Present at Jefferies Healthcare Conference
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the Jefferies Healthcare Conference, scheduled for June 7, 2023. The company's leadership, including the CEO and CFO, will engage in a fireside chat to discuss its clinical-stage biopharmaceutical developments. Arbutus focuses on innovative therapies targeting viral diseases, with current efforts in Hepatitis B and SARS-CoV-2 among others. This presentation aims to enhance the company's visibility in the biopharma sector.
Read more →ABUSArbutus to Present at JMP Securities Life Sciences Conference
Arbutus Biopharma Corporation will present at the JMP Securities Life Sciences Conference on May 16, 2023. The company's executives, including the CEO and CFO, will participate in a fireside chat, which will also be available via live webcast. Arbutus focuses on developing therapeutics for viral diseases, with ongoing clinical evaluations for its lead compound, AB-729, among other initiatives.
Read more →ABUSArbutus Reports First Quarter 2023 Financial Results and Corporate Update
Arbutus Biopharma Corporation has reported its first quarter 2023 financial results and provided a corporate update, highlighting advancements in its pipeline. Significant progress was made with AB-729, showing durable effects in patients, while new trials for AB-161 and a coronavirus candidate, AB-343, are set to commence. However, the company faced challenges with AB-101 as its trial was placed on clinical hold by the FDA. Financially, the company is stable, with a cash runway into early 2025 despite a decrease in revenue from the prior year.
Read more →ABUSArbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
Arbutus Biopharma Corporation announced encouraging results for its hepatitis B treatments AB-729 and AB-161 during the Global Hepatitis Summit 2023. Clinical data showed that 78% of patients treated with AB-729 maintained low HBV DNA and HBsAg levels for over a year and a half after treatment. Additionally, preclinical findings for AB-161 indicated significant anti-HBV activity, suggesting it could be an important component of a future treatment regimen. The company is committed to continuing research and development for these innovative therapies.
Read more →ABUSArbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
Arbutus Biopharma Corporation announced that its Investigational New Drug application for AB-101, an oral PD-L1 inhibitor, is on clinical hold as per the FDA's verbal communication. This hold prevents the company from advancing with the Phase 1 clinical trial and reporting initial data as previously scheduled. The official Clinical Hold letter from the FDA is expected within 30 days. This presents significant challenges for the future development of AB-101, which aims to enhance the immune response in chronic hepatitis B patients.
Read more →ABUSArbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation has announced the schedule for its first quarter 2023 financial results and corporate update, set for May 4, 2023. The event will include a press release at 7:30 a.m. ET and a conference call/webcast at 8:45 a.m. ET. The company is focused on developing therapies for viral diseases, including ongoing phase 2 trials for its lead compound AB-729 aimed at providing a functional cure for chronic Hepatitis B.
Read more →ABUSArbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
Arbutus Biopharma Corporation has announced that two abstracts regarding their therapies AB-729 and AB-161 have been accepted for oral presentations at the Global Hepatitis Summit 2023. AB-729 has shown promising results in reducing HBsAg in chronic hepatitis B patients, while AB-161 has demonstrated robust antiviral activity as a potential oral treatment. The presentations are scheduled for April 27, 2023, in Paris. This event showcases Arbutus's advancements in addressing chronic HBV infections, providing hope for better treatment options.
Read more →ABUSArbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
Arbutus Biopharma and Genevant Sciences have filed a patent infringement lawsuit against Pfizer and BioNTech in the U.S. District Court, claiming damages for the unauthorized use of their patented lipid nanoparticle (LNP) technologies in COVID-19 mRNA vaccines. The lawsuit focuses on several specific patents related to the manufacturing and delivery of mRNA therapeutics. Arbutus argues that these technologies were essential for the rapid development of effective vaccines during the pandemic. The outcome of the lawsuit may significantly impact Arbutus's financial standing and IP strategy moving forward.
Read more →ABUSArbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
Arbutus Biopharma Corporation has announced the successful dosing of the first subject in a Phase 1 clinical trial evaluating its oral RNA destabilizer, AB-161, targeting hepatitis B virus (HBV). This trial aims to assess the safety, tolerability, and pharmacokinetics of the treatment. The company anticipates initial data from this single-ascending dose trial by the second half of 2023, representing a step forward in developing a potential functional cure for chronic HBV infection.
Read more →ABUSArbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
Arbutus Biopharma presented preclinical data for AB-343, an oral SARS-CoV-2 Mpro inhibitor, at the 36th International Conference on Antiviral Research. The data indicates that AB-343 exhibits strong antiviral potency and selectivity, demonstrating effectiveness against various SARS-CoV-2 variants and other coronaviruses. The company plans to continue with IND-enabling studies and intends to initiate a Phase 1 clinical trial in the second half of 2023. These developments are viewed as a promising step towards addressing the urgent need for effective antiviral therapies.
Read more →ABUSArbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
Arbutus Biopharma Corporation has reported its financial results and corporate updates for Q4 and the year 2022, highlighting progress in advancing its clinical programs for chronic HBV and COVID-19. The company anticipates releasing important data from several ongoing clinical trials in 2023, including for its RNAi therapeutic AB-729 and other candidates like AB-101 and AB-161. Despite reporting a net loss of $69.5 million for the year, Arbutus remains in a solid financial position with sufficient cash to fund operations into Q4 2024 and looks forward to numerous clinical milestones ahead.
Read more →ABUSArbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it will report its financial results for the fourth quarter and year end of 2022 on March 2, 2023. The financial results will be released via press release at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. The update highlights the company's focus on developing therapeutics targeting viruses like Hepatitis B and SARS-CoV-2.
Read more →ABUSArbutus to Participate in Three Upcoming Investor Conferences
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its participation in three investor conferences in February and March 2023. The events include the SVB Securities Global Biopharma Conference, Cowen 43rd Annual Health Care Conference, and Jefferies Biotech on the Bay Summit. During these conferences, Arbutus will host one-on-one meetings and present its advancements in developing therapeutics targeting viral diseases, including Hepatitis B and coronavirus.
Read more →ABUSArbutus Announces Resignation of Board Member
Arbutus Biopharma Corporation announced the resignation of Tram Tran, MD from its Board of Directors, effective February 26, 2023. Dr. Tran is leaving to pursue a public service opportunity and is not resigning due to any disagreements with the company. She joined the board in November 2021 and has provided valuable insights, particularly in the areas of hepatitis B and COVID-19 therapeutics. The company will begin the search for a new independent board member immediately.
Read more →ABUSArbutus Announces 2023 Corporate Objectives and Provides Financial Update
Arbutus Biopharma Corporation announced its 2023 corporate objectives and financial updates, indicating plans to advance its HBV assets AB-101 and AB-161 into Phase 1 clinical trials. The company expects to gather data from its AB-729 HBV clinical trials in the upcoming months, aiming for a combination curative regimen. Additionally, Arbutus is set to initiate a Phase 1 clinical trial for their new coronavirus candidate, AB-343. The firm reported a robust financial standing with a cash runway projected into Q4 2024.
Read more →ABUSArbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg Initial data from IFN phase expected in the first half of 2023 WARMINSTER, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceut
Read more →ABUSArbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Financially strong with a projected cash runway into the second quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729, our RNAi therapeutic, and NA therapy On-track to achieve multiple additional mi
Read more →ABUSNASDAQ: ABUS www.arbutusbio.com November 4, 2022 AASLD Data Presentation
NASDAQ: ABUS www.arbutusbio.com November 4, 2022 AASLD Data Presentation Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All sta
Read more →ABUSArbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in combination with an RNAi, may provide enhanced HBV immune response Data to be p
Read more →ABUSArbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting 2022
Conference Call and Webcast to discuss the new data being presented at AASLD scheduled for 8:45 AM ET, Friday, November 4, 2022 WARMINSTER, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging
Read more →ABUSArbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has s
Read more →ABUSArbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference
WARMINSTER, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Com
Read more →ABUSArbutus to Participate in September Investor Conferences
WARMINSTER, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Com
Read more →ABUSArbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729
WARMINSTER, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Unit
Read more →ABUSArbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Financially strong with a projected cash runway into the second quarter of 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIR
Read more →ABUSArbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update
WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has s
Read more →ABUSArbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor
Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences’ core inhibitor, and nucleos(t)ide analog continues with data expected in 2H 2022 WARMINSTER, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:
Read more →ABUSArbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress 2022 and Provides AB-836 Clinical Update
Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress 2022 and Provides AB-836 Clinical Update AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients
Read more →ABUSArbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update
AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients who discontinued both AB-729 an
Read more →ABUSArbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ET WARMINSTER, Pa., June 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its ext
Read more →ABUSArbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapy WARMINSTER, Pa. and OXFORD, U.K., June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging i
Read more →ABUSArbutus to Participate in June Investor Conferences
WARMINSTER, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Comp
Read more →ABUSArbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that its abstr
Read more →ABUSNASDAQ: ABUS www.arbutusbio.com May 24, 2022 Corporate Presentation
NASDAQ: ABUS www.arbutusbio.com May 24, 2022 Corporate Presentation Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statemen
Read more →ABUSArbutus to Present at H.C. Wainwright Global Investment Conference
WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William C
Read more →ABUSArbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update
Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Well positioned financially with a projected cash runway into the second quarter of 2024 C
Read more →ABUSArbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has
Read more →ABUSArbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update
Anticipate reporting data from four clinical trials in chronically infected HBV patients in 2022 Expected to complete IND-enabling studies for two oral compounds (PD-L1 inhibitor AB-101 and RNA destabilizer AB-161) to treat HBV in the second half of 2022 Anticipate advancing an
Read more →ABUSArbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna
WARMINSTER, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Genevant Sciences today f
Read more →ABUSArbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has s
Read more →ABUSArbutus Announces 2022 Corporate Objectives and Provides Financial Update
Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for the treatment of HBV Complete IND-enabling studies for next generation oral RNA d
Read more →ABUSArbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cur
Read more →ABUSArbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan
Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, becomes strategic partner to provide development, manufacturing and commercialization expertise for the mainland China, Hong Kong, Macau and Taiwan markets Arbutus to receive $40 million in an upfront pay
Read more →ABUSArbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement
Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks WARMINSTER, Pa. and WALTHAM, Mass. and MUNICH, Germany, Dec. 07, 2021 (GLOBE NEWSWIRE)
Read more →ABUSPreliminary Data Shows that Arbutus' Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
Preliminary Data Shows that Arbutus' Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity WARMINSTER, Pa., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company p
Read more →ABUSArbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting
Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting Arbutus' Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to 28 weeks after discontinu
Read more →ABUSArbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors
WARMINSTER, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to
Read more →ABUSArbutus to Participate at Jefferies London Healthcare Conference
WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to
Read more →ABUSArbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021 First patient dosed in Phase 2a clinical trial combining AB-729, Peg-IFN -2a and nucleos(t)ide analog ("NA") therapy On-track
Read more →ABUSArbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting 2021
WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of actio
Read more →ABUSArbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of actio
Read more →ABUSCorporate Presentation October 2021 NASDAQ: ABUS www.arbutusbio.com NASDAQ: ABUS www.arbutusbio.com Forward - Looking Statements 2 This presentation contains forward - looking statements within the meaning of the U . S .
Corporate Presentation October 2021 NASDAQ: ABUS www.arbutusbio.com NASDAQ: ABUS www.arbutusbio.com Forward - Looking Statements 2 This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canad
Read more →ABUSArbutus to Participate in October Investor Conferences
WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as wel
Read more →ABUSArbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well
Read more →ABUSArbutus to Participate in Upcoming Investor Conferences
WARMINSTER, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well
Read more →ABUSArbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update
New data on AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress™; all AB-729 abstracts selected for best of ILC™ Announced two additional proof-of-concept clinical collaborations to evaluate AB-
Read more →ABUSArbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
WARMINSTER, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well a
Read more →ABUSArbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update
WARMINSTER, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well a
Read more →ABUSCorporate Presentation July 2021 NASDAQ: ABUS www.arbutusbio.com
Corporate Presentation July 2021 NASDAQ: ABUS www.arbutusbio.com NASDAQ: ABUS www.arbutusbio.com Forward - Looking Statements 2 This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian
Read more →ABUSArbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent
Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic hepatitis B virus infection (CHB) WARMINSTER, Pa., July 07, 2021 (GLOBE NEWSWIRE) --
Read more →ABUSArbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
WARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate an innovative ther
Read more →ABUSArbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection
MENDHAM, N.J. and WARMINSTER, Pa., June 29, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination of Arbutus’ pro
Read more →ABUSArbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress 2021 - All Selected for Best of ILC
Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress 2021 - All Selected for Best of ILC AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparab
Read more →ABUSArbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™
AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks AB-729 resulted in HBsAg declines below 100 IU/ml in 75% of treated subjects, and increased HBV-specific immune responses in 3/5 evaluable
Read more →ABUSArbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June
Conference Call and Webcast to discuss the new data being presented at EASL scheduled for 8:00 AM ET, Monday, June 28, 2021 WARMINSTER, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focus
Read more →ABUSArbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data Additional data from the ongoin
Read more →ABUSArbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronavirus
Read more →ABUSArbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks WARMINSTER, Pa. and WALTHAM, Mass. and MUNICH, Germany, April 01, 2021 (GLOBE NEWSWIRE)
Read more →ABUSArbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection
WARMINSTER, Pa., March 16, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronavirus
Read more →ABUSArbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, demonstrates robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data Reductions in HBsAg seen in both HBV DNA ne
Read more →ABUSArbutus to Participate at H.C. Wainwright Global Life Sciences Conference
WARMINSTER, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronavirus
Read more →ABUSArbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruse
Read more →ABUSCorporate Presentation February 2021 NASDAQ: ABUS www.arbutusbio.com
Corporate Presentation February 2021 NASDAQ: ABUS www.arbutusbio.com NASDAQ: ABUS www.arbutusbio.com Forward - Looking Statements 2 This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Cana
Read more →ABUSArbutus Announces 2021 Corporate Objectives and Provides Financial Update
Arbutus Announces 2021 Corporate Objectives and Provides Financial Update 2021 objectives leverage positive momentum in Arbutus' Hepatitis B research and development programs WARMINSTER, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clin
Read more →ABUSArbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruse
Read more →ABUSArbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects
Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks (–1.44 log10, N=7, p<0.7) AB-729 remains generally safe and well tolerated with no SAEs or treatment discontinuations in any cohort WARMINST
Read more →ABUSArbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience , The American Association f
Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience , The American Association for the Study of Liver Diseases Meeting Across all single-dose cohorts, mean HBsAg concentrations co
Read more →ABUSArbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects
Data released today expands on November 15, 2020 AASLD presentation Repeat dosing of 60 mg AB-729 every 4 weeks resulted in robust and continuous mean declines in HBsAg decline at week 20 (-1.71 log10IU/mL, N=7) and further reductions continued beyond week 20 (-1.84 log10 IU/mL,
Read more →ABUSArbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting
Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau, suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted In the 60 mg every 4 weeks multi-dose cohort, HBsAg concentrations continued t
Read more →ABUSArbutus to Present at Jefferies Virtual London Healthcare Conference
WARMINSTER, Penn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviru
Read more →ABUSArbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Results from an ongoing Phase 1a/1b clinical trial for Arbutus’ AB-729, a subcutaneously delivered RNAi agent, in subjects with chronic hepatitis B virus (HBV) infection, to be presented at the upcoming American Association for the Study of Liver Disease (AASLD) Conference Clini
Read more →ABUSArbutus to Report Third Quarter 2020 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruse
Read more →ABUSArbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
WARMINSTER, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses
Read more →ABUSArbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference
WARMINSTER, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruse
Read more →ABUSArbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg Mean HBsAg reduction of 1.23 log 10 IU mL at week 12 with a favorable s
Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg Mean HBsAg reduction of 1.23 log10 IU mL at week 12 with a favorable safety and tolerability profile WARMINSTER, Pa., -- Arbutus
Read more →ABUSArbutus to Participate in Virtual Fireside Chat at H.C. Wainwright 22nd Annual Global Investment Conference
WARMINSTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronavirus
Read more →ABUSArbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020 AB-836, an oral capsid inhibitor, remains on track for completion of IND enabling studies by the end of 2020 A
Read more →ABUSdeck8k Corporate Presentation August 2020 NASDAQ: ABUS www.arbutusbio.com Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Refo
Corporate Presentation August 2020 NASDAQ: ABUS www.arbutusbio.com Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements that a
Read more →ABUSArbutus to Report Second Quarter 2020 Financial Results
WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruse
Read more →ABUSArbutus to Present at Jefferies Virtual Healthcare Conference
WARMINSTER, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today announced that William Collier, Arbutus’ Presid
Read more →ABUSForward-Looking Statements and Information This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934
Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period 9
Read more →ABUSArbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg
Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period 90 mg single-dose and 60 mg multi-dose cohorts initiated with data expected in the second half of 2020 Conference Call and Webcast Scheduled Today at 4:30 P
Read more →ABUSArbutus to Present at UBS Virtual Global Healthcare Conference
WARMINSTER, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today announced that William Collier, Arbutus’ Presid
Read more →ABUSArbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections
Arbutus remains on track to achieve its key 2020 objectives despite COVID-19 challenges Conference Call and Webcast Scheduled Today at 8:00 AM ET WARMINSTER, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical c
Read more →ABUSArbutus to Report First Quarter 2020 Financial Results
WARMINSTER, Pa., May 04, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its first quarter financial results, conference call and webcast for Monday, May 11, 2020
Read more →ABUSArbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B
Positive single dose AB-729 data in chronic hepatitis B subjects supports further clinical development First multiple dose cohort results expected in second half of 2020 One or more additional single dose cohorts planned to further optimize antiviral response and dosing frequen
Read more →ABUSimplied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated pre-clinical studies and clinical trials may be more costly or take longer to complete than anticipated, a
Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B Positive single dose AB-729 data in chronic hepatitis B subjects supports further clini
Read more →ABUSArbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update Conference Call and Webcast Scheduled Today at 8:45 AM ET Warminster, PA
Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update Conference Call and Webcast Scheduled Today at 8:45 AM ET Warminster, PA - March 5, 2020 - Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatit
Read more →ABUSArbutus to Report Fourth Quarter and Year-End 2019 Financial Results
WARMINSTER, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and Year-End 2019 financial results, conference call and webcast for
Read more →ABUSArbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer
Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020 WARMINSTER, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), announced today its decision to discontinue AB-452, its first generation orally available hepatitis B (HBV
Read more →ABUSArbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update Conference Call and Webcast Scheduled Today at 8:45 AM ET Warminster, PA
Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update Conference Call and Webcast Scheduled Today at 8:45 AM ET Warminster, PA - Nov. 06, 2019 - Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, t
Read more →ABUSArbutus to Report Third Quarter 2019 Financial Results
WARMINSTER, Pa., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its third quarter financial results, conference call and webcast for Wednesday, November
Read more →ABUSArbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B
WARMINSTER, Pa., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue the clinical development of AB-506, an oral capsid inhibitor. AB-506 was in a Phas
Read more →ABUSArbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors
WARMINSTER, Pa., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Andrew Cheng, M.D., Ph.D., has been appointed to the Arbutus Board of Directors effecti
Read more →ABUSSingularly Focused on HBV August 2019 NASDAQ: ABUS www.arbutusbio.com Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform
Singularly Focused on HBV August 2019 NASDAQ: ABUS www.arbutusbio.com Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements t
Read more →ABUSArbutus to Participate at Wedbush PacGrow Healthcare Conference
WARMINSTER, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia will present at the Wedbush PacGrow Healthcare Conference on Tuesday,
Read more →ABUSArbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- Appointed William Collier, with decades of leadership experience in antivirals, President & CEO - Announced preliminary Phase 1a/1b clinical trial results demonstrating that AB-506 is a potent capsid inhibitor in subjects with chronic hepatitis B - Initiated dosing in healthy
Read more →ABUSArbutus to Report Second Quarter 2019 Financial Results
WARMINSTER, Pa., July 29, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its second quarter financial results, conference call and webcast for
Read more →ABUSArbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B
Results demonstrate that AB-506 is a potent capsid inhibitor Phase 1a/1b clinical trial to continue with the enrollment of further cohorts Conference call and webcast scheduled today at 4:45 pm ET WARMINSTER, Pa., July 15, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation
Read more →ABUSArbutus Sells Part of its ONPATTRO™ (patisiran) Royalty Interest to OMERS
- Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant downstream economics - Runway extended with non-dilutive capital WARMINSTER, Pa., July 02, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-lead
Read more →ABUSArbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729
- AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production - Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral capsid inhibitor WARMINSTER, Pa., June 20, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopha
Read more →ABUSArbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D.
WARMINSTER, Pa., June 17, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of William H. Collier as President and Chief Executive Officer, effective Ju
Read more →ABUSArbutus to Participate at JMP Securities Life Sciences Conference
WARMINSTER, Pa., June 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia and Dr. Gaston Picchio will participate in a fireside chat at JMP Sec
Read more →ABUSSingularly on HBV May 2019 Focused NASDAQ: ABUS www.arbutusbio.com Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act
Singularly on HBV May 2019 Focused NASDAQ: ABUS www.arbutusbio.com Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements that a
Read more →ABUSArbutus to Present at Upcoming May 2019 Conferences
WARMINSTER, Pa., May 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and CEO, will present at the following conference
Read more →ABUSArbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update
Top-line safety and efficacy results from an interim analysis of the initial Phase 1a/1b clinical trial of AB-506, a proprietary oral capsid inhibitor, expected in July 2019 Conference Call and Webcast Scheduled Today at 4:30 PM ET WARMINSTER, Pa., May 06, 2019 (GLOBE NEWSWIRE)
Read more →ABUSArbutus to Report First Quarter 2019 Financial Results
WARMINSTER, Pa., April 29, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its first quarter financial results, conference call and webcast for
Read more →ABUSArbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives
- Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg - Ongoing analyses of AB-452, a novel orally-available RNA destabilizer, with a go/no go decision expected in the second half of the year
Read more →ABUSArbutus to Present at Cowen Health Care Conference
WARMINSTER, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark Murray, Arbutus’ President and CEO, will present a corporate overview and bus
Read more →ABUSArbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and year-end 2018 financial results conference call
Read more →ABUSSingularly Focused on HBV Corporate Overview | February 2019 NASDAQ: ABUS www.arbutusbio.com Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securit
Singularly Focused on HBV Corporate Overview | February 2019 NASDAQ: ABUS www.arbutusbio.com Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities l
Read more →ABUSArbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors
WARMINSTER, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Frank Torti has been appointed as Chairman of the Company’s Board of Directors, eff
Read more →ABUSArbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update
- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial - ONPATTRO™ (patisiran) approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), triggering a royalty stream to Arbutus Third Qu
Read more →ABUSArbutus to Report Third Quarter 2018 Financial Results
WARMINSTER, Pa., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its third quarter financial results, conference call and webcast for W
Read more →ABUSArbutus Names New Members to its Board of Directors
WARMINSTER, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that James Meyers and Myrtle Potter have been appointed to the Arbutus Board of Directors, e
Read more →ABUSArbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer
WARMINSTER, Pa., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a change to its executive leadership team and provided an update on its key HBV development
Read more →ABUSArbutus to Present at Chardan’s Genetic Medicines Conference
WARMINSTER, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and Chief Executive Officer, will present at the
Read more →ABUSArbutus to Participate at the 2018 B. Riley FBR Healthcare Conference
WARMINSTER, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, will participate in the Hepatitis
Read more →ABUSArbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloidosis
ONPATTRO Approval Triggers Royalty to Arbutus Clinically Validated LNP Technology Now in the Hands of Genevant to Develop RNA-based Products WARMINSTER, Pa., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (H
Read more →ABUSArbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference
WARMINSTER, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, will present a corporate update a
Read more →ABUSArbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update
- Phase 1a/1b study of AB-506, a second-generation oral capsid inhibitor, initiated - Phase 1a/1b study of AB-452, a novel and proprietary oral RNA destabilizer, expected to begin in the second half of 2018 - All oral combination Phase 2 study of AB-506 and AB-452 expected to b
Read more →ABUSArbutus to Report Second Quarter 2018 Financial Results
WARMINSTER, Pa., July 19, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its second quarter financial results, conference call and webcast for T
Read more →ABUSArbutus Presents Corporate Update on Key Milestones
First Subject Dosed in Phase 1 Study of AB-506, Arbutus’ Second-Generation Capsid Inhibitor All-Oral Combination Study of AB-506 and AB-452 Expected in 2019 HBsAg Reduction Data from ARB-1467 Expected in Q4 Arbutus Spinout Genevant Enters Transformative Partnership with Leadin
Read more →ABUSArbutus Biopharma to Present at First Annual Roivant Pipeline Day
VANCOUVER, British Columbia and WARMINSTER, Pa., June 18, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will present at the first annual Roivant Pipeline Day
Read more →ABUSArbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer
VANCOUVER, British Columbia and WARMINSTER, Pa., June 07, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of David Hastings as Chief Financial Officer,
Read more →ABUSArbutus Announces Corporate Update and First Quarter 2018 Financial Results
Two Novel HBV Candidates Planned to Enter Clinical Development in 2018 GalNAc Conjugated RNAi Agent Nominated to Enter IND-Enabling Studies Strategic Partnership with Roivant to Launch Genevant, an RNA Therapeutics Company Company to Host a Corporate Update Conference Call Tod
Read more →ABUSArbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results
VANCOUVER, British Columbia and WARMINSTER, Pa., April 30, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 3, 2018
Read more →ABUSArbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018
Capsid inhibitor with HBV RNA Destabilizer Demonstrate Complementary Efficacy Results Subcutaneous RNAi Agent Demonstrates Durable HBsAg Reduction Following a Single Dose VANCOUVER, British Columbia and WARMINSTER, Pa., April 12, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corpo
Read more →ABUSArbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases
Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platforms Genevant will be led by Executive Chairman Paris Panayiotopoulos, former CEO of ARIAD Pharmaceuticals through
Read more →ABUSArbutus to Present HBV Data at 2018 EASL Liver Meeting
VANCOUVER, British Columbia and WARMINSTER, Pa., March 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of data at the 53rd Annual International Liver
Read more →ABUSArbutus Announces Corporate Update and Year-End 2017 Financial Results
ARB-1467 Phase II Combination Study Beginning in 1Q18 Two New Drug Candidates Planned to Enter Clinical Development in 2H18 Over $200M in Cash Available to Fund Development of HBV Assets Company to Host a Corporate Update Conference Call Today at 4:30 PM ET VANCOUVER, British
Read more →ABUSArbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results
VANCOUVER, British Columbia and WARMINSTER, Pa., March 12, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Wednesday, March 14,
Read more →ABUSArbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology
Acuitas has No Further Rights to Use or Sublicense Arbutus LNP Technology Arbutus Consolidates LNP Patent Estate Enabling RNAi, mRNA, and Gene-editing Therapeutics VANCOUVER, B.C. and WARMINSTER, Pa., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS)
Read more →ABUSArbutus Enters Exclusivity Agreement with Roivant Sciences
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that Arbutus and Roivant entered into an exclusivity agreemen
Read more →ABUSArbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that Bruce Cousins, Executive Vice President and Chief Finan
Read more →ABUSArbutus Consolidates HBV Business Around Warminster, PA Site
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a site consolidation and organizational restructuring to bett
Read more →ABUSArbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant Sciences NOT FOR IMMEDIATE RELEASE
Arbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant Sciences NOT FOR IMMEDIATE RELEASE: January 16, 2018 Vancouver, BC and Warminster, PA - Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading hepatitis B virus (HBV) therap
Read more →ABUSArbutus Announces Presentations at HepDART 2017
VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced two oral presentations and one poster presentation at HepDART
Read more →ABUSArbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran
VANCOUVER, B.C. and WARMINSTER, Pa., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company's lipid nanoparticle (LNP) licensee Alnylam Pharmaceutic
Read more →ABUSArbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company's lipid nanoparticle (LNP) licensee Alnylam
Read more →ABUSArbutus Announces Corporate Update and Third Quarter 2017 Financial Results
Strategic Investment from Roivant Extends Cash Runway Combination Study for ARB-1467 Starting in 4Q17 Company to Host a Corporate Update Conference Call Today at 4:15 PM ET VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Cor
Read more →ABUSArbutus Announces Conference Call to Provide a Corporate Update and Third Quarter 2017 Financial Results
VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, November 2,
Read more →ABUSArbutus Presents HBV Data at 2017 AASLD Liver Meeting
Phase 2 ARB-1467 Combination Study Starting in 4Q17 Expected IND-filings in 2018 for Two New Oral Compounds VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV
Read more →ABUSArbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences
VANCOUVER, British Columbia and WARMINSTER, Pa. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, and Roivant Sciences Ltd. announced today the closing of the issue and sale
Read more →ABUSArbutus to Present HBV Data at 2017 AASLD Liver Meeting
VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of data at The Liver Meeting® 2017 organized by
Read more →ABUSArbutus to Receive $116 Million Strategic Investment from Roivant Sciences Cash to Provide Significant Support for Arbutus to Fund HBV R&D Pipeline Roivant to Support Accelerating Development of Arbutus HBV Pipeline and
Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences Cash to Provide Significant Support for Arbutus to Fund HBV R&D Pipeline Roivant to Support Accelerating Development of Arbutus HBV Pipeline and Maximizing the Value of Arbutus LNP Assets Vancouver, BC
Read more →ABUSArbutus to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the company will present a corporate overview and busin
Read more →ABUSArbutus Announces Topline Results for ARB-1467 Phase II Cohort 4
VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced topline results of the bi-weekly dosing segment of Cohort 4 of the
Read more →ABUSArbutus Presents HBV Data at Upcoming Scientific Conferences
VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of HBV data at the following scientific confere
Read more →ABUSArbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
Arbutus’ LNP Technology Further Validated with New Results Arbutus to Receive Single Digit Royalties on Sales of Patisiran VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepati
Read more →ABUSArbutus to Host Live Webinar on Developments of LNP Delivery for mRNA-based Therapeutics
VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, announced today that it will host a live, informational webinar titled, “LNP
Read more →ABUSArbutus to Present at 2017 Wedbush PacGrow Healthcare Conference
VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the company will present a corporate overview and busine
Read more →ABUSArbutus Announces Corporate Update and Second Quarter 2017 Financial Results
Two New Drug Candidates Nominated for Development ARB-1740 Development Update Company to Host a Corporate Update Conference Call Today at 4:30 PM ET VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS),
Read more →ABUSArbutus Announces Conference Call to Provide a Corporate Update and Second Quarter 2017 Financial Results
VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, August 3, 20
Read more →ABUSArbutus Announces Conclusion of LNP License Agreement with Alexion
Alexion Decision Driven by Strategic Review of R&D Activities Collaboration Enabled Further Optimization of LNP for Delivery of mRNA Arbutus Views LNP as a Potential Source of Significant Non-Dilutive Capital VANCOUVER, British Columbia and WARMINSTER, Pa., July 27, 2017 (GLOB
Read more →ABUSArbutus Presents HBV Drug Combination Studies at ICAR
Combinations of Arbutus’ RNAi or Capsid Assets with Approved Drugs Demonstrate Complementary Activity Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer, Awarded International Society of Antiviral Research Gertrude Elion Award VANCOUVER, British Columbia and WARMINSTER, Pa
Read more →ABUSArbutus Announces Corporate Update and First Quarter 2017 Financial Results
3 HBV Product Candidates Progressing in Clinical Development Cash Runway to Late 2018 Company to Host a Corporate Update Conference Call Today at 4:30 PM ET VANCOUVER, British Columbia and WARMINSTER, Pa., May 04, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:
Read more →ABUSArbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2017 Financial Results
VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 02, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 4, 2017 a
Read more →ABUSArbutus Announces ARB-1467 Data Presentation at EASL
ARB-1467 Reduces Serum HBsAg in Both HBeAg Negative and HBeAg Positive Patients Results of Biweekly Dosing from Cohort 4 Expected in 3Q17 Additional Study Starting in 2H17 to Evaluate Longer Term Dosing with Immune Modulatory Agents VANCOUVER, British Columbia and WARMINSTER,
Read more →ABUSArbutus Injunction Survives Attempted Appeal by Acuitas
VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 13, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that a justice of the Court of Appeal for British Columbia d
Read more →ABUSArbutus Announces Appointment of Daniel Burgess to Board of Directors
VANCOUVER, B.C. and DOYLESTOWN, Pa., March 23, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company has appointed Daniel Burgess to the Board of Directors
Read more →ABUSArbutus Announces Year-End 2016 Financial Results
3 HBV Product Candidates in the Clinic in 1Q17 Cash Runway into Late 2018 Company to Host a Corporate Update Conference Call Today at 2:00 PM ET VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 21, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an
Read more →ABUSArbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate
VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced it has li
Read more →ABUSArbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced that the S
Read more →ABUSArbutus Provides Additional Data from the ARB-1467 Phase II Clinical Trial in HBV Patients
Complete Cohort 1 and 2 ARB-1467 Multi-Dose Data Demonstrate Dose-Responsive HBsAg Reductions Greater Than 1.0 log10 Reduction in Serum HBsAg Observed in 3/5 Patients After Receiving Three Monthly Doses of ARB-1467 at 0.4 mg/kg Company to Host Conference Call to Review Phase II
Read more →ABUSArbutus Presents HBV Drug Combination Studies at AASLD
Combinations of Arbutus RNAi and Capsid Assets and Approved Drugs Show Complementary Action Capsid Inhibitor AB-423 Has Dual Mode of Action; Inhibits HBV DNA and cccDNA Synthesis Second Generation RNAi Agent ARB-1740 Improves Upon Potency of Lead RNAi Program VANCOUVER, B.C. a
Read more →ABUSArbutus Provides Corporate Update and Announces Third Quarter 2016 Financial Results
Additional ARB-1467 Multi-Dose Data in 4Q16 Cash Runway into Late 2018 VANCOUVER, B.C. and DOYLESTOWN, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced
Read more →ABUSArbutus Recognizes Liver Cancer Awareness Month with Grant to Support the Hepatitis B Foundation’s Patient Storytelling Campaign
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a partnership with the Hepatitis B Foundation to support the
Read more →ABUSArbutus to Present HBV Data at the 2016 AASLD Liver Meeting
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Oct. 01, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today announced presentation of data at the 2016 American Association for the
Read more →ABUSArbutus Reports Interim Multi-Dose Results from Phase II Clinical Trial of ARB-1467 in Patients with Chronic HBV Infection
Single Dose Data Demonstrate Significant Reduction in Serum HBsAg Additive Reductions in Serum HBsAg Observed with Repeat Dosing over 3 Months 5 of 6 Patients in Cohort 1 Had Serum HBsAg Reductions of Greater Than 0.5 log10 After 3 Doses Additional Multi-Dose ARB-1467 Data Exp
Read more →ABUSArbutus’ Chief Scientific Officer, Dr. Michael J. Sofia, Awarded the 2016 Lasker~DeBakey Clinical Medical Research Award
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer
Read more →ABUSArbutus to Present at the 2016 Wedbush PacGrow Healthcare Conference
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be presenting at the Wedbush PacGrow He
Read more →ABUSArbutus Announces Issuance of Broad New US Patent for LNP Delivery Technology
Patent Covers Lipid Particle Compositions Known to be Effective for Delivery of Nucleic Acids Including mRNA VANCOUVER, B.C. and DOYLESTOWN, Pa., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeuti
Read more →ABUSArbutus Provides Corporate Update and Announces Second Quarter 2016 Financial Results
ARB-1467 Clinical Data in HBV Patients on Track for 2H16 Cash Runway Extends into Late 2018 VANCOUVER, British Columbia and DOYLESTOWN, Pa., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic so
Read more →ABUSArbutus Reports Topline Results from TKM-PLK1 HCC Clinical Trial
Promising Anti-Tumor Activity Observed Arbutus to Explore Partnership Options to Enable Further Study VANCOUVER, B.C. and DOYLESTOWN, Pa., July 19, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solu
Read more →ABUSArbutus to Present Data on New LNP Formulations for Delivery of mRNA at the 2016 Controlled Release Society Conference
In Vivo Data Support Improved Potency of New Lipid Compositions Arbutus’ LNP Platform is the Leading Delivery Solution for mRNA Therapeutics VANCOUVER, British Columbia and DOYLESTOWN, Pa., July 18, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an indust
Read more →ABUSArbutus to Present mRNA Delivery Data at the 32nd Annual Meeting of the Japan Society of Drug Delivery System
In Vivo Data Support Use of Our Proprietary LNP Platform Technology Arbutus Has a Dominant IP Position in LNP-Enabled Delivery VANCOUVER, British Columbia and DOYLESTOWN, Pa., June 30, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hep
Read more →ABUSArbutus to Present at the 5th Antiviral Drugs Research and Development Conference
First In Vivo Data from Arbutus HBV Preclinical Combination Studies Additive Anti-HBV Effects When Combining Capsid Inhibitor AB-423 with Current Standard of Care VANCOUVER, British Columbia and DOYLESTOWN, Pa., June 01, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (N
Read more →ABUSArbutus Provides Corporate Update and Announces First Quarter 2016 Financial Results
VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 04, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced its first quarter 2016 unaudited financial results and provide
Read more →ABUSArbutus Expands HBV Pipeline
VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today announced a licensing and research collaboration agreement with the Sain
Read more →ABUSArbutus to Provide a Corporate Update and Release First Quarter 2016 Financial Results
VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 29, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call and webcast on Wednesday
Read more →ABUSArbutus Presents Data from Combination Activity Studies of HBV Drug Candidates
Additional Preclinical Combination Data to be Presented This Year Clinical Combination Studies to Begin in 2017 VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 22, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus
Read more →ABUSArbutus Announces Planned Executive Departure
VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 21, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Patrick T. Higgins, Arbutus’ Chief Business Officer has
Read more →ABUSArbutus Announces Planned Executive Departure VANCOUVER, British Columbia and DOYLESTOWN, Pa.
Arbutus Announces Planned Executive Departure VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 21, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Patrick
Read more →ABUSArbutus Presents Data on HBV Capsid Assembly Inhibitor AB-423 at EASL 2016
Synergistic Antiviral Activity When Combining AB-423 With Entecavir IND Filing (or Equivalent) Expected in the Second Half of 2016 VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 14, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leadin
Read more →ABUSArbutus to Present Preclinical HBV Data at EASL 2016
VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 30, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the European Association for the Study of the Liver (EA
Read more →ABUSArbutus Announces Year-End 2015 Financial Results
VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 09, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced its 2015
Read more →ABUSArbutus Appoints Dr. Elizabeth Howard Executive Vice President and General Counsel
VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 08, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced the appoi
Read more →ABUSArbutus Biopharma to Participate in Upcoming Investor Conferences
VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced that the
Read more →ABUSArbutus Provides a Corporate Update and Outlines 2016 Milestones
Phase II Multidose Study of ARB-1467 in HBV Patients Was Initiated in 2015 Phase II Single Dose HBsAg Reduction Data Expected in 3Q16 Four HBV Products in Clinical Development by Year-End VANCOUVER, British Columbia and DOYLESTOWN, Pa., Jan. 10, 2016 (GLOBE NEWSWIRE) -- Arbutu
Read more →ABUSArbutus Biopharma Announces Third Quarter 2015 Financial Results
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced its third q
Read more →ABUSArbutus Provides an HBV Pipeline Update
TKM-HBV Progressing to Phase II in HBV Infected Patients by Year-End TKM-HBV Phase II S-Antigen Reduction Data Expected in 2016 Initiation of Proprietary Combination Studies in HBV Infected Patients Expected in 2017 Conference Call Scheduled for 7:30AM Pacific VANCOUVER, Brit
Read more →ABUSArbutus Biopharma Presents Preclinical Data at the 2015 International Meeting on Molecular Biology of Hepatitis B Viruses
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Oct. 6, 2015 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced three prese
Read more →ABUSArbutus to Present TKM-HBV Data at the 2015 AASLD Liver Meeting
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Oct. 1, 2015 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced presentatio
Read more →ABUSArbutus to Present at the Baird 2015 Healthcare Conference
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced that Mr. A
Read more →ABUSArbutus Announces Initiation of Patient Dosing in the TKM-PLK1 HCC Expansion Cohort
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Aug. 25, 2015 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced the initia
Read more →ABUSArbutus to Present at 2015 Wedbush PacGrow Healthcare Conference
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced that Dr. Ma
Read more →ABUSArbutus Biopharma Announces Second Quarter 2015 Financial Results
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced its second
Read more →ABUSArbutus to Present at Jefferies Hepatitis B Summit
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced that Dr. Ma
Read more →ABUSArbutus Biopharma Corporation (Nasdaq: ABUS) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Aug. 03, 2015 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B virus infection (HBV), will vi
Read more →ABUSArbutus Biopharma (NASDAQ: ABUS) Finalizes Corporate Name Change From Tekmira Pharmaceuticals
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) today announced finalization of its corporate name change from Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR). Arbutus Biopharma ("Arbutus") is an indu
Read more →ABUSTekmira Announces Completion of Underwritten Public Offering of Common Shares FOR IMMEDIATE RELEASE
Tekmira Announces Completion of Underwritten Public Offering of Common Shares Vancouver, B.C. Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announ
Read more →ABUSTekmira Announces Pricing of Underwritten Public Offering of Common Shares FOR IMMEDIATE RELEASE
Tekmira Announces Pricing of Underwritten Public Offering of Common Shares Vancouver, B.C. Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced
Read more →ABUSAGREEMENT AND PLAN OF MERGER AND REORGANIZATION
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This Agreement and Plan of Merger and Reorganization (" Agreement") is made and entered into as of January 11, 2015, by and among Tekmira Pharmaceuticals Corporation, a British Columbia corporation (" Parent"); TKM Acquisition Corp
Read more →ABUSTEKMIRA PHARMACEUTICALS CORPORATION MATERIAL CHANGE REPORT FORM 51-102F3 1. Name and Address of Company: Tekmira Pharmaceuticals Corporation (the Company ) 100 - 8900 Glenlyon Parkway Glenlyon Business Park Burnaby, B.C.
TEKMIRA PHARMACEUTICALS CORPORATION MATERIAL CHANGE REPORT Tekmira Pharmaceuticals Corporation (the 100 - 8900 Glenlyon Parkway Glenlyon Business Park A new release announcing the material change was issued by the Company on January 13, 2014. A copy of the news release is a
Read more →ABUSTEKMIRA PHARMACEUTICALS CORPORATION Unaudited Interim Condensed Consolidated Financial Statements (expressed in Canadian dollars) (Prepared in accordance with generally accepted accounting principles used in the United S
TEKMIRA PHARMACEUTICALS CORPORATION Unaudited Interim Condensed Consolidated Financial Statements (expressed in Canadian dollars) (Prepared in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP)) Three and nine months end
Read more →ABUSEXECUTION COPY 3,750,000 Common Shares TEKMIRA PHARMACEUTICALS CORPORATION (incorporated under the Business Corporations Act ( British Columbia ))
3,750,000 Common Shares TEKMIRA PHARMACEUTICALS CORPORATION (incorporated under the Business Corporations Act (British Columbia)) UNDERWRITING AGREEMENT NICOLAUS & COMPANY, INCORPORATED As Representative of the several Underwriters named in Schedule I hereto One Montgomery
Read more →ABUSCROSS-LICENSE AGREEMENT By and Among ALNYLAM PHARMACEUTICALS, INC. TEKMIRA PHARMACEUTICALS CORPORATION And PROTIVA BIOTHERAPEUTICS INC. Dated
CROSS-LICENSE AGREEMENT ALNYLAM PHARMACEUTICALS, INC. TEKMIRA PHARMACEUTICALS CORPORATION PROTIVA BIOTHERAPEUTICS INC. Dated: November 12, 2012 ARTICLE I DEFINITIONS 2 ARTICLE II LICENSE GRANTS AND RELATED RIGHTS 12 2.1 License Grants to Tekmira 12 2.2 License Gra
Read more →ABUSTEKMIRA PHARMACEUTICALS CORPORATION MATERIAL CHANGE REPORT FORM 51-102F3 1. Name and Address of Company: Tekmira Pharmaceuticals Corporation (the "Company") 100 - 8900 Glenlyon Parkway Glenlyon Business Park Burnaby, B.C
TEKMIRA PHARMACEUTICALS CORPORATION MATERIAL CHANGE REPORT Tekmira Pharmaceuticals Corporation (the "Company") 100 - 8900 Glenlyon Parkway Glenlyon Business Park The news release announcing the material change disclosed in this material change report is attached as Schedule
Read more →ABUSSchedule "A" Tekmira Secures $3 Million Financing Financial Guidance Updated: Cash Runway Further Extended into 2013
Tekmira Secures $3 Million Financing Financial Guidance Updated: Cash Runway Further Extended into 2013 Vancouver, BC - Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR, TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, announced it has secured a US$3.0 m
Read more →ABUSTEKMIRA 2011 OMNIBUS SHARE COMPENSATION PLAN (as approved by the board of directors on
TEKMIRA 2011 OMNIBUS SHARE COMPENSATION PLAN (as approved by the board of directors on May 10, 2011 and approved by the shareholders at the June 22, 2011 Annual and Special General Meeting) TEKMIRA PHARMACEUTICALS CORPORATION TEKMIRA PHARMACEUTICALS CORPORATION 2011 OMNIBUS S
Read more →ABUSTekmira Closes $5.1 Million Public Offering FOR IMMEDIATE RELEASE
Tekmira Closes $5.1 Million Public Offering Vancouver, BC - Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR, TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, has closed its previously announced public offering of 1,789,900 units for total gross proceeds
Read more →ABUSAGENCY AGREEMENT
Tekmira Pharmaceuticals Corporation 8900 Glenlyon Parkway Attention: Dr. Mark J. Murray, President and Chief Executive Officer We understand that Tekmira Pharmaceuticals Corporation (the Corporation ) proposes to appoint Versant Partners Inc. (the Agent ) to offer for sale, u
Read more →ABUSTekmira Prices Public Offering
Tekmira Prices Public Offering Vancouver, BC - Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR, TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today it has priced a public offering of units at a price of Cdn$2.85 per unit. Each unit consists
Read more →ABUSTekmira Announces Proposed Public Offering
Tekmira Announces Proposed Public Offering Vancouver, BC - Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR, TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has undertaken an offering of units, each unit being comprised of one com
Read more →ABUSTekmira and the National Cancer Institute Publish Promising Data Demonstrating the Anti-Tumor Activity of a Novel Cancer Target FOR IMMEDIATE RELEASE
Tekmira and the National Cancer Institute Publish Promising Data Demonstrating the Anti-Tumor Activity of a Novel Cancer Target Vancouver, BC Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR, TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, announced to
Read more →Competitive Position
How ABUS ranks across every disease it competes inCompetitive Position is a premium feature
See how ABUS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial